Traditional Chinese medicine composition for treating ischemic bowel disease as well as preparation method and application thereof

The therapeutic drugs prepared by the water extraction method of Qinli and Chuanxiong Chinese medicine compositions solved the problem of ischemic enteropathy treatment, significantly alleviating intestinal mucosal damage and vascular permeability, inhibiting intestinal adhesions, improving intestinal peristalsis function, and providing the best Effective treatment plan for ischemic bowel disease.

CN118903246AActive Publication Date: 2024-11-08FOURTH MILITARY MEDICAL UNIVERSITY
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202410876748.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-02
Publication Date
2024-11-08
Estimated Expiration
2044-07-02

AI Technical Summary

Technical Problem

There are fewer existing drugs for the treatment of ischemic bowel disease, complex pathological mechanisms, lack of ideal treatment measures, and commonly used treatment methods may lead to reperfusion injury and increase the difficulty of treatment.

Method used

Provided is a traditional Chinese medicine composition composed of Qinli and Chuanxiong. The weight ratio of Qinli and Chuanxiong is 1:0.5-3. It is used to prepare drugs for the treatment of ischemic enteropathy, prepare water extracts through water extraction method, and combine pharmaceutical auxiliary materials. Prepare capsules, granules or tablets in oral or enema administration form to improve intestinal mucosal damage, reduce vascular permeability and inhibit intestinal adhesion.

Benefits of technology

It significantly reduces intestinal mucosa damage, reduces vascular permeability, inhibits intestinal adhesions, improves intestinal peristalsis function, has good effect in treating ischemic enteropathy, and is suitable for acute and chronic mesenteric ischemia and ischemic colitis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004923289370000051
    Figure BDA0004923289370000051
  • Figure BDA0004923289370000052
    Figure BDA0004923289370000052
  • Figure BDA0004923289370000053
    Figure BDA0004923289370000053
Patent Text Reader

Abstract

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating ischemic bowel disease as well as a preparation method and application thereof. The traditional Chinese medicine composition is prepared from gentiana macrophylla and ligusticum wallichii, and the weight part ratio of gentiana macrophylla to ligusticum wallichii is 1: (0.5-3). The traditional Chinese medicine composition disclosed by the invention can be used for treating ischemic bowel diseases such as acute mesenteric ischemia, chronic mesenteric ischemia and ischemic colitis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating ischemic bowel disease, and a preparation method and application thereof. Background Art

[0002] Ischemic bowel disease is a common digestive tract disease in clinical practice. It is mainly caused by insufficient arterial blood supply or obstructed venous return in the small intestine, colon and other parts, resulting in ischemic hypoxic necrosis of the intestinal wall. The clinical onset is often acute, and the main manifestations are bloody stools, diarrhea and severe abdominal pain. The key to treatment is to restore intestinal blood circulation as quickly as possible. Clinically, surgery, thrombolysis and intervention are often used to restore blood supply as quickly as possible. However, this will lead to more serious reperfusion injury, increasing the difficulty of treating the disease. The causes of ischemic bowel disease involve acute and chronic mesenteric ischemia, vascular obstructive and non-obstructive ischemia, etc. The pathological mechanism is complex, and there is currently no ideal treatment measure.

[0003] At present, there are few reports on therapeutic drugs for ischemic bowel disease. The present application proposes a Chinese medicine composition for treating ischemic bowel disease, and a preparation method and use thereof. Summary of the invention

[0004] In order to solve the above problems, the present invention provides a Chinese medicine composition for treating ischemic bowel disease and its preparation method and application. The Chinese medicine composition of the present invention has a good therapeutic effect on ischemic bowel disease.

[0005] Therefore, the first object of the present invention is to provide a traditional Chinese medicine composition for treating ischemic bowel disease, which is made of Gentiana macrophylla and Ligusticum chuanxiong, and the weight ratio of Gentiana macrophylla to Ligusticum chuanxiong is 1:0.5-3.

[0006] In a specific implementation, the weight ratio of Gentiana macrophylla to Ligusticum chuanxiong can be 1:0.5 or 1:1 or 1:1.5 or 1:2 or 1:2.5 or 1:3.

[0007] Preferably, the weight ratio of Gentiana macrophylla to Ligusticum chuanxiong is 1:0.8-2.7, more preferably 1:1-2.5.

[0008] Preferably, the weight ratio of Gentiana macrophylla to Ligusticum chuanxiong is 1:1.5-2.2, more preferably 1:1.8-2.2, and even more preferably 1:2.

[0009] In a specific implementation manner, the weight ratio of the Gentiana macrophylla and Ligusticum chuanxiong is 50-200:50-200, preferably 80-170:80-170.

[0010] The second object of the present invention is to provide the use of the above-mentioned Chinese medicine composition in the preparation of medicines for treating ischemic bowel disease.

[0011] Preferably, the ischemic bowel disease is selected from the group consisting of acute mesenteric ischemia, chronic mesenteric ischemia and ischemic colitis.

[0012] In a specific embodiment, the drug is used to improve intestinal mucosal atrophy and shedding of intestinal villi, reduce inflammatory infiltration of intestinal epithelial cells, and maintain intestinal barrier function.

[0013] In a specific embodiment, the drug is used to reduce vascular endothelial cell damage, reduce acute ischemic damage to the mesentery, and improve intestinal vascular permeability.

[0014] In a specific embodiment, the drug is used to reduce intestinal adhesions and fibrotic lesions of adhesion tissues, and inhibit the distribution and deposition of collagen in adhesion tissues.

[0015] The third object of the present invention is to provide the use of Gentiana macrophylla and / or Ligusticum chuanxiong in the preparation of medicines for treating ischemic bowel disease.

[0016] Preferably, the water extract of Gentiana macrophylla and / or the water extract of Ligusticum chuanxiong are used in the preparation of a medicament for treating ischemic bowel disease.

[0017] The preparation of the water extract of Gentiana macrophylla and / or Rhizoma Chuanxiong comprises the following steps: crushing the Chinese medicinal raw materials Gentiana macrophylla and / or Rhizoma Chuanxiong, adding water for reflux extraction, filtering, combining the filtrate and concentrating it into a thick paste.

[0018] The fourth object of the present invention is to provide a medicine for treating ischemic bowel disease, which comprises the above-mentioned Chinese medicine composition and pharmaceutically acceptable excipients.

[0019] Preferably, the drug is administered orally or by enema, preferably orally.

[0020] Preferably, the medicine is a decoction, powder, pill, granule, tablet, capsule, syrup or mixture, more preferably a capsule, granule or tablet.

[0021] The fifth object of the present invention is to provide a method for preparing the drug for treating ischemic bowel disease, which comprises the following steps: crushing the Chinese medicinal raw materials Gentiana macrophylla and Ligusticum chuanxiong, soaking them in 6 to 10 times the amount of water, refluxing and extracting them 2 to 3 times, each time for 1 to 3 hours, filtering, combining the filtrate and concentrating it into a thick paste.

[0022] Preferably, the Chinese medicinal raw materials Gentiana macrophylla and Ligusticum chuanxiong are crushed (for example, cut into pieces) and extracted twice, with 8 times the amount of water added for the first time and refluxed for 2 hours, and with 6 times the amount of water added for the second time and refluxed for 1.5 hours, filtered, and the filtrates are combined and concentrated into a thick paste (relative density of 1.25-1.30 (50-60°C)).

[0023] Preferably, the method for preparing the drug for treating ischemic bowel disease further comprises the following steps:

[0024] The thick paste is dried and crushed, dextrin or lactose is added, 90% ethanol is used as a binder, and granules are prepared, and the granules are filled into capsules after drying to obtain capsules; or

[0025] Adding soluble starch and sucrose to the thick paste, wherein the mass ratio of the thick paste to the soluble starch and sucrose is 1-2:0.5-2:0.5-1, making wet granules, drying and sieving the whole granules to obtain granules; or

[0026] The thick paste is dried and crushed, starch is added, and 90% ethanol is used as a binder to prepare wet granules. After drying, the granules are sized, magnesium stearate and / or polyethylene glycol and / or sodium carboxymethyl starch and / or low-substituted hydroxypropyl cellulose (L-HPC) are added, and then tableting is performed to obtain tablets; wherein the mass ratio of the dry paste powder to starch, magnesium stearate or polyethylene glycol, low-substituted hydroxypropyl cellulose (L-HPC) or sodium carboxymethyl starch is 3-5:3-5:0.1-0.3:0.5-1.

[0027] The Chinese medicine composition for treating ischemic bowel disease of the present invention can treat acute mesenteric ischemia, chronic mesenteric ischemia and ischemic colitis caused by vascular obstructive and non-obstructive ischemia. Pharmacodynamic experiments show that the Chinese medicine composition of Gentiana macrophylla-Ligusticum chuanxiong (the Chinese medicine pair of Gentiana macrophylla-Ligusticum chuanxiong) can significantly reduce intestinal mucosal damage, reduce vascular permeability and inhibit intestinal adhesion, and has a significant therapeutic effect on ischemic bowel disease. DETAILED DESCRIPTION

[0028] Typical embodiments are listed below to further illustrate the present invention, but do not constitute limitations on the protection scope of the present invention.

[0029] Preparation Example 1

[0030] Cut and mix the Chinese medicinal raw materials Gentiana macrophylla 89g and Ligusticum chuanxiong 178g (1:2), put them into a round-bottom flask, add water and boil them twice. For the first time, add 8 times the amount of water, boil them for 2h, filter and keep the filtrate for later use; for the second time, add 6 times the amount of water, boil them for 1.5h, filter and combine the filtrates to concentrate them into a thick paste (50-60°C) with a relative density of 1.25-1.30. The thick paste is vacuum dried and crushed to obtain a dry paste powder. An equal amount of dextrin is added and 90% ethanol is used as a binder to granulate. After drying, the whole granules are filled into capsules to prepare capsules.

[0031] Preparation Example 2

[0032] The capsules were prepared in the same manner as in Example 1, except that the Chinese medicinal raw materials were 93 g of Gentiana macrophylla and 93 g of Ligusticum chuanxiong (1:1).

[0033] Preparation Example 3

[0034] The capsules were prepared in the same manner as in Example 1, except that the Chinese medicinal raw materials were 192 g of Gentiana macrophylla and 96 g of Ligusticum chuanxiong (2:1).

[0035] Preparation Example 4

[0036] Cut and mix the Chinese medicinal raw materials Gentiana macrophylla 168g and Ligusticum chuanxiong 84g (2:1), put them into a round-bottom flask, add water and boil them twice. For the first time, add 8 times the amount of water, boil them for 2 hours, filter and keep the filtrate for later use; for the second time, add 6 times the amount of water, boil them for 1.5 hours, filter and combine the filtrates to concentrate them into a thick paste (50-60°C) with a relative density of 1.25-1.30. Add soluble starch and sucrose to the thick paste, wherein the mass ratio of the thick paste to the soluble starch and sucrose is 1:2:1, make wet granules, dry and sieve the whole granules to obtain granules.

[0037] Preparation Example 5

[0038] Granules were prepared in the same manner as in Example 4, except that the Chinese medicinal raw materials were 84 g of Gentiana macrophylla and 168 g of Ligusticum chuanxiong (1:2), and the mass ratio of the thick paste to the soluble starch and sucrose was 1:1.5:0.5.

[0039] Preparation Example 6

[0040] Granules were prepared in the same manner as in Example 4, except that the Chinese medicinal raw materials were 126 g Gentiana macrophylla and 126 g Chuanxiong (1:1), and the mass ratio of the thick paste to the soluble starch and sucrose was 2:1.5:1.

[0041] Preparation Example 7

[0042] 92g of Chinese medicinal raw materials Gentiana macrophylla and 184g of Chuanxiong (1:2) were chopped and mixed, then put into a round-bottom flask, and decocted twice with water. For the first time, 8 times the amount of water was added, decocted for 2h, filtered, and the filtrate was reserved; for the second time, 6 times the amount of water was added, decocted for 1.5h, filtered, and the filtrate was combined and concentrated into a thick paste (50-60°C) with a relative density of 1.25-1.30, and the thick paste was vacuum dried and crushed to obtain a dry paste powder, starch was added, and wet granules were made with 90% ethanol as a binder. After drying, the granules were sized, magnesium stearate and low-substituted hydroxypropyl cellulose (L-HPC) were added, and then tablets were obtained; wherein the mass ratio of the dry paste powder to starch, magnesium stearate, and low-substituted hydroxypropyl cellulose (L-HPC) was 3:3:0.3:1.

[0043] Preparation Example 8

[0044] Tablets were prepared by the same method as in Example 7, except that the Chinese medicinal raw materials were 132 g of Gentiana macrophylla and 66 g of Ligusticum chuanxiong (2:1), and the mass ratio of dry paste powder to starch, magnesium stearate, and sodium carboxymethyl starch was 3:4:0.1:0.5.

[0045] Preparation Example 9

[0046] Tablets were prepared by the same method as in Example 7, except that the Chinese medicinal raw materials were 121 g of Gentiana macrophylla and 121 g of Ligusticum chuanxiong (1:1), and the mass ratio of dry paste powder to starch, polyethylene glycol, and low-substituted hydroxypropyl cellulose (L-HPC) was 4:4:0.2:0.8.

[0047] The following test examples are used to further illustrate the extraction and preparation process of the Chinese medicine composition of the present invention and its therapeutic effect on ischemic bowel disease.

[0048] Test Example 1: Study on extraction process

[0049] (1) Selection of the amount of water added: In order to explore the process conditions of water extraction of the Chinese medicine composition, the amount of solvent water added during extraction was investigated with the yield of thick paste as an indicator. Weigh the medicinal materials, three times in total, add water according to A (10 times the amount for the first time, 8 times the amount for the second time), B (8 times the amount for the first time, 6 times the amount for the second time), and C (6 times the amount for the first time, 6 times the amount for the second time), decoct twice, 2 hours for the first time, and 1.5 hours for the second time, filter, combine the filtrates and concentrate them into a thick paste with a relative density of 1.25-1.30 (50-60°C), and calculate the yield of the thick paste (see Table 1).

[0050] Table 1 Results of water addition

[0051]

[0052] The test results show that, taking the yield of thick paste as the evaluation index, the yield of thick paste is not much different between adding 10 times the amount of water for the first time and 8 times the amount of water for the second time and adding 8 times the amount of water for the first time and 6 times the amount of water for the second time. From the perspective of energy saving, it is more appropriate to add 8 times the amount of water for the first time and 6 times the amount of water for the second time.

[0053] (2) Selection of decoction times: In order to explore the process conditions of water extraction of the Chinese medicine composition, the thick paste yield was used as an indicator to investigate the decoction times during extraction. Weigh the medicinal materials, three portions in total, add water and decoct. For the first time, add 8 times the amount of water, decoct for 2 hours, filter, and reserve the filtrate; for the second and third times, add 6 times the amount of water, decoct for 1.5 hours, filter, and combine the filtrates to concentrate into a thick paste with a relative density of 1.25-1.30 (50-60°C). Calculate the thick paste yield (see Table 2).

[0054] Table 2 Results of investigation on decoction times

[0055]

[0056] The test results show that, taking the yield of thick paste as the evaluation index, the yield of thick paste when decocted twice is not much different from that when decocted three times, which means that the extraction is basically complete after decocting twice. Considering energy saving and time saving, it is more appropriate to choose to decoct twice.

[0057] (3) Selection of decoction time: In order to explore the process conditions of water extraction of the Chinese medicine composition, the decoction time during extraction was investigated with the yield of thick paste as an indicator. Weigh the medicinal materials, three portions in total, add water and decoct, add 8 times the amount of water for the first time and 6 times the amount of water for the second time, decoct A (2h, 2h), B (2h, 1.5h), C (1.5h, 1.5h) respectively, filter, combine the filtrate and concentrate it into a thick paste (50-60℃) with a relative density of 1.25-1.30, and calculate the yield of thick paste (see Table 3).

[0058] Table 3 Decoction time investigation results

[0059]

[0060] The test results show that, taking the yield of thick paste as the evaluation indicator, there is little difference between each extraction for 2 hours and the first extraction for 2 hours and the second extraction for 1.5 hours. Considering energy and time saving, it is more appropriate to choose the first extraction for 2 hours and the second extraction for 1.5 hours.

[0061] Test Example 2: Study on the Formulation Process

[0062] The dry paste powder after drying and crushing has poor fluidity and is easy to absorb moisture and deteriorate, and needs to be prepared into preparations, such as capsules.

[0063] Since the dry powder has poor fluidity and is not easy to be directly loaded into capsules, it is first prepared into granules. The present invention investigates the granulation effects of starch, dextrin, lactose and mannitol as auxiliary materials, and granulates with dry powder: auxiliary materials = 1:1 and 90% ethanol as a wetting agent.

[0064] Table 4 Screening of excipients

[0065]

[0066] From the results in Table 4, it can be seen that the granulation effect of dextrin is the best. Dextrin is selected as the auxiliary material for granulation, and the whole granules are filled into capsules after drying to make capsules.

[0067] Experimental Example 3: Chinese herbal medicine composition alleviates intestinal mucosal damage after ischemia-reperfusion in mice

[0068] Healthy adult male C57BL / 6J mice were used in this experiment, and subsequent experiments were conducted after 1 week of adaptive feeding. The experimental process and related operations were approved by the Experimental Animal Center of the Fourth Military Medical University.

[0069] Experimental grouping and administration: Using the samples of Preparation Examples 4 to 6, mice were divided into a normal group, a model group, a group of Gentiana macrophylla alone, a group of Rhizoma Chuanxiong alone, a group of Gentiana macrophylla-Rhizoma Chuanxiong (1:2), a group of Gentiana macrophylla-Rhizoma Chuanxiong (1:1), and a group of Gentiana macrophylla-Rhizoma Chuanxiong (2:1); an intestinal ischemia-reperfusion injury (IIRI) model was used to simulate ischemic intestinal disease, i.e., the superior mesenteric artery of mice was clamped for 45 minutes of ischemia and then reperfused for 90 minutes for modeling. After modeling, the mice were continuously gavaged for 7 days, and the serum and intestinal tissue of the mice were collected for subsequent experiments.

[0070] Implementation methods: Hematoxylin-eosin (H&E) staining of mouse intestinal tissue and Chiu's score of intestinal mucosa. The mouse intestinal tissue was fixed in 4% paraformaldehyde for 24 hours, then embedded in paraffin and sliced. The tissue sections were soaked in xylene I and II for 30 minutes respectively; then soaked in different concentrations of ethanol in turn, rinsed with distilled water for 3 minutes; then H&E staining was performed; neutral resin was used to seal the slides, and the slides were observed and photographed under an optical microscope. The pathological changes of intestinal mucosa were scored using the Chiu's score. The grades are as follows: 0 points, normal; 1 point, the subepithelial space at the top of the villi is widened; 2 points, the subepithelial space at the top of the villi is further widened, the epithelium at the tip of the villi is elevated and peeled off from the lamina propria; 3 points, the villus epithelium falls off in blocks; 4 points, the epithelium is completely shed, and only the lamina propria is left; 5 points, the lamina propria layer collapses, and bleeding and ulcers occur.

[0071] The results showed that after 7 days of water administration, the model group developed edema, blood stasis and even intestinal adhesion in the small intestine, while the edema and adhesion were significantly alleviated after treatment with the combination of Qinjiao and Chuanxiong. The combination of Qinjiao and Chuanxiong significantly reduced intestinal mucosal atrophy, shedding of intestinal villi, inflammatory infiltration of intestinal epithelial cells, and Chiu's score of intestinal mucosal damage (Table 5).

[0072] Table 5 Effects of different ratios of Gentiana macrophylla-Ligusticum chuanxiong on intestinal mucosa

[0073]

[0074] Compared with the model group, *P<0.05, **P<0.01

[0075] Experimental Example 4: Chinese herbal medicine composition alleviates acute mesenteric ischemia injury after ischemia-reperfusion in mice

[0076] Experimental method: Based on Experimental Example 3, serum samples were taken from each group of mice, and the levels of D-dimer (D2D) and intestinal fat-binding protein (iFABP) were detected according to the operating instructions of the ELISA kit.

[0077] Statistical analysis: GraphPad Prism 8.4.0 software was used to analyze and calculate the statistical data.

[0078] ˉ

[0079] The data are expressed as mean ± standard deviation (x ± s). The t-test was used for comparison among the groups. P < 0.05 indicated a significant difference.

[0080] Experimental results: D2D is closely related to the formation of thrombus in the blood circulation, and iFABP can reflect the severity of villus damage during intestinal ischemia. Both of the above indicators are markers of acute mesenteric ischemia. The experimental results showed that the levels of D2D and iFABP in the model group increased significantly, indicating that acute mesenteric ischemia was caused in mice after modeling, and different ratios of Gentiana macrophylla-Chuanxiong could significantly reduce the levels of D2D and iFABP, indicating that the Chinese medicine composition of the present invention can alleviate acute mesenteric ischemia damage (Table 6).

[0081] Table 6 D2D and iFABP levels in different ratios of Gentiana macrophylla-Ligusticum chuanxiong groups

[0082]

[0083] Compared with the model group, *P<0.05, **P<0.01

[0084] Experimental Example 5: Chinese herbal medicine composition improves intestinal motility in mice after intestinal ischemia-reperfusion injury

[0085] Implementation method: Based on Experiment 3, each group of mice was fed with a semi-solid nutrient paste containing carbon powder, and the effect of each group of drug treatment on the peristaltic function of the small intestine was evaluated by calculating the distance of the carbon powder nutrient paste in the mouse intestine within a fixed time. After each group of mice was treated, 0.3 ml / 10 g of semi-solid nutrient paste containing carbon powder was fed, and the mice were killed after 30 minutes of free activity. The whole small intestine was taken from the pylorus to the ileocecal valve, and the small intestine propulsion rate was calculated (calculation formula: small intestine propulsion rate = [propulsion distance of carbon powder (cm) / length of the whole small intestine (cm)] × 100%).

[0086] Statistical analysis: GraphPad Prism 8.4.0 software was used to analyze and calculate the statistical data.

[0087] ˉ

[0088] The data are expressed as mean ± standard deviation (x ± s). The t-test was used for comparison among the groups. P < 0.05 indicated a significant difference.

[0089] Experimental results: The propulsion rate of carbon powder nutrient paste in the small intestine of mice in the model group was reduced, indicating that the small intestinal motility slowed down and the intestinal function was impaired after ischemia-reperfusion injury; while the propulsion rates of the small intestine of mice in the Qinjiao-Chuanxiong (1:2) group, Qinjiao-Chuanxiong (1:1) group and Qinjiao-Chuanxiong (2:1) group were significantly increased, and the intestinal motility function was improved, among which the Qinjiao-Chuanxiong (1:2) group had the most significant effect (Table 7), indicating that the Chinese medicine composition of the present invention can improve the intestinal motility function of mice after intestinal ischemia-reperfusion injury.

[0090] Table 7 Small intestinal propulsion rate of mice in different ratios of Gentiana macrophylla-Ligusticum chuanxiong groups

[0091]

[0092]

[0093] Compared with the model group, **P<0.01

[0094] Experimental Example 6: Chinese herbal medicine composition improves intestinal adhesion after intestinal ischemia-reperfusion injury in mice

[0095] Experimental method: Based on Experimental Example 3, H&E staining was used to evaluate the intestinal adhesion of each group of mice.

[0096] Experimental results: After the intestinal barrier is damaged, a large number of inflammatory factors are released to trigger intestinal adhesions, and exudates containing fibrin are deposited and coagulated to form a fibrous network, causing extensive intestinal dysfunction. The results showed that the mice in the model group had peritoneal effusion after 7 days, severe adhesion of abdominal tissues, especially intestinal adhesions, and dense fibrous structures at the adhesions; after being treated with different ratios of Gentiana macrophylla-Chuanxiong, the intestinal adhesions of mice were significantly reduced, indicating that the Chinese medicine composition of the present invention can reduce intestinal adhesions after intestinal ischemia-reperfusion injury in mice.

[0097] Based on the above description of the invention, those skilled in the art can fully apply the present invention, and all the same principles or similar modifications should be deemed to be included in the scope of the present invention.

Claims

1. A Chinese medicine composition for treating ischemic bowel disease, characterized in that: The invention is prepared from qinjiao and chuanxiong, and the weight ratio of qinjiao to chuanxiong is 1:0.5-3.

2. The Chinese medicine composition according to claim 1, characterized in that: The weight ratio of Gentiana macrophylla to Ligusticum chuanxiong is 1:0.8-2.7, and more preferably 1:1-2.

5.

3. The Chinese medicine composition according to claim 1, characterized in that The weight ratio of Gentiana macrophylla to Ligusticum chuanxiong is 1:1.5-2.2, more preferably 1:1.8-2.2, and even more preferably 1:

2.

4. Use of the Chinese medicine composition according to claim 1 in the preparation of a medicament for treating ischemic bowel disease.

5. The use according to claim 4, characterized in that: The ischemic bowel disease is selected from the group consisting of acute mesenteric ischemia, chronic mesenteric ischemia and ischemic colitis; Preferably, the drug is used to improve intestinal mucosal atrophy, shedding of intestinal villi, reduce inflammatory infiltration of intestinal epithelial cells, and maintain intestinal barrier function; or, Preferably, the drug is used to reduce vascular endothelial cell damage, reduce acute ischemic damage to the mesentery, and improve intestinal vascular permeability; or, Preferably, the drug is used to reduce intestinal adhesion and fibrotic lesions of adhesion tissue, and inhibit collagen distribution and deposition in adhesion tissue.

6. Use of Gentiana macrophylla and / or Rhizoma Chuanxiong in the preparation of a medicament for treating ischemic bowel disease; preferably, use of Gentiana macrophylla water extract and / or Rhizoma Chuanxiong water extract in the preparation of a medicament for treating ischemic bowel disease.

7. A drug for treating ischemic bowel disease, characterized in that: The invention comprises the Chinese medicine composition according to any one of claims 1 to 3 and pharmaceutically acceptable excipients.

8. The drug according to claim 7, characterized in that The medicine is administered orally or by enema, preferably by oral administration; the medicine is a decoction, powder, pill, granule, tablet, capsule, syrup or mixture, preferably a capsule, granule or tablet.

9. A method for preparing the drug according to claim 7 or 8, characterized in that: The following steps are involved: Crush the Chinese medicinal materials Gentiana macrophylla and Chuanxiong, soak them in 6-10 times the amount of water, reflux extract 2-3 times, each time for 1-3 hours, filter, combine the filtrate and concentrate it into a thick paste; Preferably, the Chinese medicinal raw materials Gentiana macrophylla and Ligusticum chuanxiong are crushed and extracted twice, the first time 8 times the amount of water is added for reflux extraction for 2 hours, the second time 6 times the amount of water is added for reflux extraction for 1.5 hours, filtered, and the filtrates are combined and concentrated into a thick paste.

10. The method for preparing the drug according to claim 9, characterized in that: The following steps are also included: The thick paste is dried and crushed, dextrin or lactose is added, 90% ethanol is used as a binder, and granules are prepared, and the granules are filled into capsules after drying to obtain capsules; or Adding soluble starch and sucrose to the thick paste, wherein the mass ratio of the thick paste to the soluble starch and sucrose is 1-2:0.5-2:0.5-1, making wet granules, drying and sieving the whole granules to obtain granules; or The thick paste is dried and crushed, starch is added, and 90% ethanol is used as a binder to prepare wet granules. After drying, the granules are sized, magnesium stearate and / or polyethylene glycol and / or sodium carboxymethyl starch and / or low-substituted hydroxypropyl cellulose (L-HPC) are added, and then tableting is performed to obtain tablets; wherein the mass ratio of the dry paste powder to starch, magnesium stearate or polyethylene glycol, low-substituted hydroxypropyl cellulose (L-HPC) or sodium carboxymethyl starch is 3-5:3-5:0.1-0.3:0.5-1.

Citation Information

Patent Citations

  • Medicament composition for ischemic disease and application thereof in medicinal preparation

    CN101461843A

  • Traditional Chinese medicine combination for treating gout and preparation method thereof

    CN101590166A

  • Application of gentiopicroside to medicine for treating inflammatory bowel diseases

    CN102716143A